Search results
The guideline has attempted to devise effective strategies for the reduction of CVD that take a combined approach using both ‘high-risk’ and population approaches. 1.1.1 UPDATING THE EVIDENCE This guideline updates SIGN 97: Risk estimation and the prevention of cardiovascular disease to reflect the most recent evidence.
Evidence. ESTIMATING CARDIOVASCULAR RISK. Individuals with the following risk factors should be considered at high risk of cardiovascular events: established cardiovascular disease, or. stage 3 or higher chronic kidney disease or micro- or macroalbuminuria, or. familial hypercholesterolaemia, or. who are over the age of 40 and have diabetes, or.
This guideline deals with the management of cardiovascular risk, both primary prevention, defined as the potential for intervention prior to the disease presenting through a specified event (any incident linked to critical disruption of blood flow that may cause damage to the heart, brain or peripheral tissues), and secondary prevention ...
30 sie 2024 · This 2024 guideline, developed by a multidisciplinary Task Force, updates the 2018 ESC/ESH guidelines on the management of arterial hypertension, using the most robust contemporary evidence.
28 sie 2019 · This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
The 2020 ISH Global Hypertension Practice Guidelines were developed by the ISH Hypertension Guidelines Committee based on evidence criteria, (1) to be used globally; (2) to be fit for application in low and high resource settings by advis-ing on essential and optimal standards; and (3) to be concise, simplified, and easy to use.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular
